IE56092B1 - Novel benzodioxole derivatives,processes for the manufacture thereof and corresponding pharmaceutical compositions - Google Patents

Novel benzodioxole derivatives,processes for the manufacture thereof and corresponding pharmaceutical compositions

Info

Publication number
IE56092B1
IE56092B1 IE2472/83A IE247283A IE56092B1 IE 56092 B1 IE56092 B1 IE 56092B1 IE 2472/83 A IE2472/83 A IE 2472/83A IE 247283 A IE247283 A IE 247283A IE 56092 B1 IE56092 B1 IE 56092B1
Authority
IE
Ireland
Prior art keywords
radical
compound
general formula
alk
given above
Prior art date
Application number
IE2472/83A
Other versions
IE832472L (en
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IE832472L publication Critical patent/IE832472L/en
Publication of IE56092B1 publication Critical patent/IE56092B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Light Receiving Elements (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Waveguide Switches, Polarizers, And Phase Shifters (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pyrane Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1. Claims (for the Contracting States : BE, CH, LI, DE, FR, GB, IT, LU, NL, SE) Compounds of the general formula I see diagramm : EP0107622,P32,F1 in which R1 represents an alkyl, alkenyl or alkynyl radical that is unsubstituted or substituted by halogen having an atomic number of up to 35, lower alkoxy or by lower alkylthio and has, in total, that is to say including the substituents, a maximum of 12 carbon atoms, or represents a phenyl or naphthyl radical that is unsubstituted or substituted by lower alkyl, lower cycloalkyl, lower alkoxy, lower alkylthio, lower alkylsulphonyl, trifluoromethyl, hydroxy, lower alkanoyl, lower alkanoylamino, lower alkoxycarbonylamino and/or by lower alkylsulphonylamino, a monocyclic five-membered hetero ring of aromatic character having two nitrogen atoms or one nitrogen atom and/or one oxygen or sulphur atom in the ring or a six-membered hetero ring of aromatic character having one or two nitrogen atoms in the ring, or a bicyclic radical consisting of the said five- or six-membered hetero rings of aromatic character with a fused benzene ring, alk represents an alkylene, alkenylene or alkylidene radical having a maximum of 5 carbon atoms, n1 represents 0, 1 or 2 and n2 represents 0 or 1, R2 , R3 and R4 each represents, independently of the others, hydrogen, lower alkyl, lower alkoxy or halogen, and A represents the radical -O-R5 wherein R5 represents hydrogen or an alkyl radical having a maximum of 12 carbon atoms that is unsubstituted or is substituted by lower alkoxy or by halogen, 2- or 3-lower alkenyl, 2-lower alkynyl, phenyl-lower alkyl or cinnamyl, in which the phenyl radical may be substituted in the same manner as under R1 , or A represents the radical see diagramm : EP0107622,P33,F1 in which either R6 and R7 each represents, independently of the other, hydrogen or lower alkyl, or R6 and R7 are bonded to one another and, together with the adjacent nitrogen atom, represent optionally lower alkyl-substituted tetra- to hexa-methyleneimino, 4-morpholinyl or 1H-tetrazol-1-yl, salts of compounds of the general formula I in which A represents OR5 wherein R5 represents hydrogen, with bases, and acid addition salts of compounds of the general formula I in which the radical R1 has a basic character, radicals designated "lower" having a maximum of 7 carbon atoms. 1. Claims (for the Contracting State AT) A process for the manufacture of compounds of the formula I see diagramm : EP0107622,P36,F2 in which R1 represents an alkyl, alkenyl or alkynyl radical that is unsubstituted or substituted by halogen having an atomic number of up to 35, lower alkoxy or by lower alkylthio and has, in total, that is to say including the substituents, a maximum of 12 carbon atoms, or represents a phenyl or naphthyl radical that is unsubstituted or substituted by lower alkyl, lower cycloalkyl, lower alkoxy, lower alkylthio, lower alkylsulphonyl, trifluoromethyl, hydroxy, lower alkanoyl, lower alkanoylamino, lower alkoxycarbonylamino and/or by lower alkylsulphonylamino, a monocyclic five-membered hetero ring of aromatic character having two nitrogen atoms or one nitrogen atom and/or one oxygen or sulphur atom in the ring or a six-membered hetero ring of aromatic character having one or two nitrogen atoms in the ring, or a bicyclic radical consisting of the said five- or six-membered hetero rings of aromatic character with a fused benzene ring, alk represents an alkylene, alkenylene or alkylidene radical having a maximum of 5 carbon atoms, n1 represents 0, 1 or 2 and n2 represents 0 or 1, R2 , R3 and R4 each represents, independently of the others, hydrogen, lower alkyl, lower alkoxy or halogen, and A represents the radical -O-R5 wherein R5 represents hydrogen or an alkyl radical having a maximum of 12 carbon atoms that is unsubstituted or is substituted by lower alkoxy or by halogen, 2- or 3-lower alkenyl, 2-lower alkynyl, phenyl-lower alkyl or cinnamyl, in which the phenyl radical may be substituted in the same manner as under R1 , or A represents the radical see diagramm : EP0107622,P36,F3 in which either R6 and R7 each represents, independently of the other, hydrogen or lower alkyl, or R6 and R7 are bonded to one another and, together with the adjacent nitrogen atom, represent optionally lower alkyl-substituted tetra- to hexa-methyleneimino, 4-morpholinyl or 1H-tetrazol-1-yl, salts of compounds of the general formula I in which A represents OR5 wherein R5 represents hydrogen with bases, and acid addition salts of compounds of the general formula I in which the radical R1 has a basic character, radicals designated "lower" having a maximum of 7 carbon atoms, characterised in that a) a compound of the general formula II see diagramm : EP0107622,P37,F1 in which R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given above, or a salt thereof, is reacted with a compound of the general formula III see diagramm : EP0107622,P37,F2 in which Hal represents halogen and A has the meaning given above, or with a salt of such a compound in which A represents OR5 wherein R5 represents hydrogen, or b) in a compound of the general formula IV see diagramm : EP0107622,P37,F3 in which A**b represents carboxy, lower alkoxycarbonyl or acetyl, and R1 , alk, n1 , n2 , R2 , R3 , R4 and A have the meanings given in claim 1, the radical A**b is replaced by hydrogen, or c) for the manufacture of a compound of the general formula I in which A has the meaning given above with the exception of a radical OR5 in which R5 represents hydrogen, and R1 , alk, n2 , R2 , R3 and R4 have the meanings given above and n1 represents 1 or 2, a compound of the general formula V see diagramm : EP0107622,P37,F4 is reacted with a compound of the general formula VI R1 -(alk)n2 -S(O)n1-c -OH or with an anhydride thereof, in which A1 has the meaning given above for A with the exception of a radical OR5 in which R5 represents hydrogen, n1-c represents 1 or 2 and R2 , R3 and R4 , and R1 , alk and n2 have the meanings given above, or d) for the manufacture of a compound in which n2 is 1 or R1 is an aliphatic radical according to the definition and R1 or n2 , as the case may be, alk, n2 , R2 , R3 , R4 and A have the meanings given above, a compound of the general formula VII R1 -(alk)n2-d -Z**d in which Z**d represents a reactively esterified hydroxy group, especially halogen having an atomic number of at least 17, R1 has the meaning given above and n2 represents 1 or, if R2 is an aliphatic radical, may alternatively be 0, or a compound of the general formula VIII see diagramm : EP0107622,P37,F5 in which Z**dd (cation) represents a monovalent anion or the normal equivalent of a polyvalent anion and R1 and n1 have the meanings given above, is reacted with a salt of a compound of the general formula IX see diagramm : EP0107622,P38,F1 in which n1 , R2 , R3 , R4 and A have the meanings given in claim 1, or e) a metal compound, optionally formed in situ, of the general formula Xa or Xb R1 -(alk)n2 -M1 see diagramm : EP0107622,P38,F2 in which M1 represents a monovalent metal ion and M2 represents a divalent metal ion and R, alk and n2 have the meanings given above, is reacted with a compound of the general XIa or XIb see diagramm : EP0107622,P38,F3 see diagramm : EP0107622,P38,F4 in which Hal represents halogen and n1 , R2 , R3 , R4 and A have the meanings given above, or f) for the manufacture of a compound of the general formula I in which A represents OR5 wherein R5 represents hydrogen, and R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given above, or a salt of this compound : in a compound of the general formula XIII see diagramm : EP0107622,P38,F5 in which A**f represents a group that can be converted into the carboxy group and R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given above, the group A**f is converted into the carboxy group in free or salt form, or g) for the manufacture of a compound of the general formula I in which A has the meaning given above with the exception of a radical OR5 in which R5 represents hydrogen, and R1 , alk, n1 , n2 , R2 and R3 have the meanings given above : in a compound of the general formula XIV see diagramm : EP0107622,P38,F6 in which A**g represents a radical that can be converted into a radical CO-A1 in which A1 has the meaning given above for A with the exception of a radical OR5 in which R5 represents hydrogen, and R1 , alk, n1 , n2 , R2 , R3 and R4 have the meanings given in claim 1, the radical A**g is converted into the radical -CO-A1 , and h) if desired, a compound of the general formula I in which n1 represents 0 or 1 is oxidised to form the corresponding compound in which n1 represents 1 or 2, or i) if desired, a compound of the general formula I in which n1 represents 2 or 1 is reduced to form the corresponding compound in which n1 represents 1 or 0, and/or, if desired, a resulting compound of the general formula I is converted in a different manner known per se into a different compound of the general formula I, and/or a compound of the general formula I obtained in the form of a racemate is separated into the optical antipodes, and/or a resulting compound of the general formula I in which A represents OR5 wherein R5 represents hydrogen is converted into a salt with a base, or such a compound is freed from a resulting salt, or a resulting compound of the general formula I of basic character is converted into an acid addition salt, or such a compound is freed from a resulting salt.
IE2472/83A 1982-10-22 1983-10-21 Novel benzodioxole derivatives,processes for the manufacture thereof and corresponding pharmaceutical compositions IE56092B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH616382 1982-10-22

Publications (2)

Publication Number Publication Date
IE832472L IE832472L (en) 1984-04-22
IE56092B1 true IE56092B1 (en) 1991-04-10

Family

ID=4305256

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2472/83A IE56092B1 (en) 1982-10-22 1983-10-21 Novel benzodioxole derivatives,processes for the manufacture thereof and corresponding pharmaceutical compositions

Country Status (16)

Country Link
EP (1) EP0107622B1 (en)
JP (1) JPS5995284A (en)
AT (1) ATE30722T1 (en)
AU (1) AU567894B2 (en)
CA (1) CA1223874A (en)
DE (1) DE3374408D1 (en)
DK (1) DK485583A (en)
ES (5) ES526609A0 (en)
FI (1) FI833819A (en)
GR (1) GR78709B (en)
IE (1) IE56092B1 (en)
IL (1) IL70005A0 (en)
NO (1) NO833857L (en)
NZ (1) NZ206035A (en)
PT (1) PT77539B (en)
ZA (1) ZA837811B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158596A3 (en) * 1984-04-06 1986-08-13 Ciba-Geigy Ag Benzodioxole derivatives, process for their preparation and pharmaceutical compositions
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
HUE040020T2 (en) 2005-10-25 2019-02-28 Kalypsys Inc Salts of modulators of ppar and methods of treating metabolic disorders
CN101007798B (en) * 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 Benzodioxole derivatives and their preparation method and medicinal uses
CN101007804B (en) * 2006-01-25 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 1,3-benzodioxole-2,2-dicarboxylic acid derivatives and their preparation method and medicinal uses
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
BR112013007495A2 (en) * 2010-10-04 2024-03-12 Firmenich & Cie BENZODIOXOL DERIVATIVES AS AQUEOUS ODORANTS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872105A (en) * 1973-06-11 1975-03-18 Merrell Inc Richard Derivatives of 1,3-benzodioxole-2-carboxylic acid
GR75464B (en) * 1981-04-24 1984-07-20 Ciba Geigy
EP0107623A1 (en) * 1982-10-22 1984-05-02 Ciba-Geigy Ag Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES8703449A1 (en) 1987-02-16
NO833857L (en) 1984-04-24
ES543683A0 (en) 1987-02-16
FI833819A0 (en) 1983-10-19
EP0107622A1 (en) 1984-05-02
AU567894B2 (en) 1987-12-10
EP0107622B1 (en) 1987-11-11
JPS5995284A (en) 1984-06-01
ES8608506A1 (en) 1986-06-16
ES8603860A1 (en) 1986-01-01
GR78709B (en) 1984-09-27
PT77539A (en) 1983-11-01
ZA837811B (en) 1984-08-29
ES8703450A1 (en) 1987-02-16
CA1223874A (en) 1987-07-07
NZ206035A (en) 1987-03-06
ES543684A0 (en) 1987-02-16
DE3374408D1 (en) 1987-12-17
DK485583A (en) 1984-04-23
PT77539B (en) 1986-05-28
FI833819A (en) 1984-04-23
IE832472L (en) 1984-04-22
DK485583D0 (en) 1983-10-21
ES8601959A1 (en) 1985-11-16
ES543681A0 (en) 1986-01-01
ATE30722T1 (en) 1987-11-15
ES526609A0 (en) 1985-11-16
ES543682A0 (en) 1986-06-16
IL70005A0 (en) 1984-01-31
AU2048983A (en) 1984-05-03

Similar Documents

Publication Publication Date Title
ATE15185T1 (en) BENZHYDRYLSULFINYLACETAMIDE DERIVATIVES AND THEIR USE IN THERAPEUTICS.
FI931190A (en) TRIAZOLOPYRIDAZINFOERENINGAR, DERAS FRAMSTAELLNING OCH ANVAENDNING
DE3374408D1 (en) Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them
ES8604543A1 (en) Piperazine derivatives with anticholinergic and/or antihistaminic activity
US2701253A (en) Substituted dithiolanes
GB1384479A (en) Phosphorus-containing amidines
BR9103665A (en) INSECTICIDE COMPOSITION AND PROCESS FOR THE PRODUCTION OF A COMPOUND
ES540332A0 (en) PROCEDURE TO PREPARE NEW PIRIMIDO (2,1-B) BENZO- TIAZOLES
GB2107315B (en) Alpha epsilon alkane diisocyanates and their use in polyurethane production
ES8300724A1 (en) Benzazol derivatives, processes for their preparation, their pharmaceutical composition and their application.
DE3560829D1 (en) ENKEPHALINASE INHIBITORS
DE69114352D1 (en) Improved chemiluminescent reagents and procedures.
GB1514514A (en) Bispiperazido phosphorus and trispiperazidophosphorus compounds
ATE4951T1 (en) ISATOGEN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS FUNGICIDES.
ATE6512T1 (en) AZOLYLALKYL-2,3-DIHYDROBENZOFURANE, FUNGICIDES CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION.
MX154916A (en) PROCEDURE FOR THE PREPARATION OF 1,1-DIOXIDES OF 3,4-DIHYDRO 2H-1,2-BENZOTIAZIN-3-CARBOXAMIDE
RO85269B (en) Process for preparing 1, 2, 4-oxadiazine derivatives
ZA827040B (en) Triazinyallactams,a process for their preparation,their use as stabilizers for synthetic organic polymers and the polymers stabilized with them